REG - Oxford Biomedica PLC - Holding(s) in Company <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

29/10/2014 12:54

RNS Number : 6035U
Oxford Biomedica PLC
17 October 2014
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi


1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:ii
OXFORD BIOMEDICA PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):
Update to Total Voting Rights figure
X
3. Full name of person(s) subject to the
notification obligation:iii
VULPES LIFE SCIENCES FUND 
VULPES TESTUDO FUND
4. Full name of shareholder(s)
(if different from 3.):iv

5. Date of the transaction and date on
which the threshold is crossed or
reached:v
13 OCTOBER 2014 
6. Date on which issuer notified:
17 OCTOBER 2014
7. Threshold(s) that is/are crossed or
reached: vi, vii
<21% 


8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares

if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights x
Direct
Direct xi
Indirect xii
Direct
Indirect
GB0006648157
533,250,100
533,250,100
533,250,100
533,250,100

20.78%


B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date xiii
Exercise/
Conversion Period xiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights






C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price
Expiration date xvii
Exercise/
Conversion period xviii
Number of voting rights instrument refers to
% of voting rights xix, xx




Nominal
Delta



Total (A+B+C)
Number of voting rights
Percentage of voting rights
533,250,100
20.78%


9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi

Proxy Voting:
10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease
to hold:

12. Date on which proxy holder will cease to hold
voting rights:



13. Additional information:


14. Contact name:
Tim Watts, Chief Financial Officer
Oxford BioMedica
15. Contact telephone number:
+44 (0) 1865 783 000

This information is provided by RNS
The company news service from the London Stock Exchange
  END
HOLUBRWRSBARARA